Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition

Contributed by: Business Wire

Logo

Tags

Science

Biotechnology

Research

Pharmaceutical

Oncology

Health

Genetics

Clinical Trials

Repare Therapeutics

More Like This

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors

Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Debiopharm & WhiteLab Genomics Announce a Strategic Partnership to Advance Drug Target and Design in Oncology

First Patients Dosed in Debiopharm's Phase III Trial (LIBELULA) Investigating Debio 4326, a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

Genialis and Debiopharm Set Up Biomarker Discovery Collaboration